Prosecution Insights
Last updated: April 19, 2026

Examiner: FRITCHMAN, REBECCA M

Tech Center 1700 • Art Units: 1758 1777 1797

This examiner grants 46% of resolved cases

Performance Statistics

45.8%
Allow Rate
-19.2% vs TC avg
736
Total Applications
+35.9%
Interview Lift
1641
Avg Prosecution Days
Based on 642 resolved cases, 2023–2026

Rejection Statute Breakdown

10.9%
§101 Eligibility
8.4%
§102 Novelty
50.4%
§103 Obviousness
23.7%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
17436218 IN VIVO REVERSIBILITY OF HIGH MOLECULAR WEIGHT SPECIES Non-Final OA AMGEN INC.
17089448 Diagnostic Method Final Rejection Amazentis SA
18221934 ISOELECTRIC FOCUSING-BASED ENRICHMENT OF CHARGE VARIANT SPECIES Non-Final OA Regeneron Pharmaceuticals, Inc.
17880676 TARGET MATERIAL IDENTIFICATION METHOD Non-Final OA Taiwan Semiconductor Manufacturing Company, Ltd.
18023483 METHODS FOR FINE NEEDLE SAMPLE ANALYSIS VIA MASS SPECTROMETRY Final Rejection BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
17079110 Genetic Determination of Hormone Levels and Applications Thereof Non-Final OA The Board of Trustees of the Leland Stanford Junior University
19187629 BIOMARKER-BASED TREATMENT AND DIAGNOSTIC METHODS FOR IL-17-DEPENDENT CONDITIONS Final Rejection MOONLAKE IMMUNOTHERAPEUTICS AG
18043495 URINARY GLYCOPROTEINS FOR THE EARLY DETECTION AND TREATMENT OF AGGRESSIVE PROSTATE CANCER Final Rejection THE JOHNS HOPKINS UNIVERSITY
17633917 BIOMARKERS FOR NEURODEGENERATIVE DISORDERS Final Rejection The Johns Hopkins University
18027393 CONTINUOUS OPTICAL APTAMER SENSORS Non-Final OA University Of Cincinnati
17614140 METHODS OF DETECTING CLOSTRIDIUM DIFFICILE INFECTIONS Final Rejection Washington University
17787015 ENDOTOXIN DETECTION Non-Final OA Eli Lilly and Company
18014582 ACQUISITION METHOD OF VALUE RELATING TO TRIGLYCERIDE METABOLIC CAPACITY, PRESENTATION METHOD OF DISEASE INFORMATION, PRESENTATION METHOD OF DISEASE DIFFERENTIATION INFORMATION, PRESENTATION METHOD OF THERAPY EFFICACY INFORMATION, PRESENTATION METHOD OF THERAPEUTIC EFFECT INFORMATION, TEST REAGENT AND TEST KIT Non-Final OA THE UNIVERSITY OF OSAKA
18286403 Sample Conveying Device, Sample Analysis System, and Sample Pretreatment System Non-Final OA Hitachi High-Tech Corporation
17816076 MONITORING AND MANAGEMENT OF CELL THERAPY-INDUCED TOXICITIES Non-Final OA Kite Pharma, Inc.
17680195 BIPHASIC COATINGS WITH CHEMICAL SENSING, AND METHODS OF MAKING AND USING THE SAME Final Rejection HRL Laboratories, LLC
17259264 SUGAR CHAIN SPECIFIC TO PROSTATE CANCER, AND TEST METHOD USING SAME Non-Final OA JAPANESE FOUNDATION FOR CANCER RESEARCH
18026088 METHODS OF DETECTING AND USING BIOMARKERS FOR GLYCOGEN STORAGE DISEASES Final Rejection Duke University
17673987 METHODS AND SYSTEMS FOR EVALUATING ORGANIC CONTAMINANTS IN WATER Final Rejection CHEMTREAT, INC.
18147094 USE OF BIOMARKERS TO DETERMINE SUB-ACUTE TRAUMATIC BRAIN INJURY (TBI) IN A SUBJECT HAVING RECEIVED A HEAD COMPUTERIZED TOMOGRAPHY (CT) SCAN THAT IS NEGATIVE FOR A TBI OR NO HEAD CT SCAN Non-Final OA Abbott Laboratories
17027206 CENTRIFUGE AND METHOD FOR LOADING A DEVICE Non-Final OA LIFE TECHNOLOGIES CORPORATION
18763980 PARTICLES AND METHODS OF ASSAYING Non-Final OA Seer, Inc.
18306195 DETECTION OF AN ANALYTE OF INTEREST BY NANOESI MASS SPECTROMETRY Final Rejection Roche Diagnostics Operations, Inc.
18028235 CIRCULATING TOTAL-NT-PROBNP (GLYCOSYLATED AND UNGLYCOSYLATED NT-PROBNP) AND ITS RATIO WITH NT-PROBNP (UNGLYCOSYLATED NT-PROBNP) IN THE ASSESSMENT OF ATRIAL FIBRILLATION Non-Final OA Roche Diagnostics Operations, Inc.
18125708 METHOD FOR DETERMINING THE LEVEL OF VITAMIN D AND METABOLITES THEREOF Non-Final OA Roche Diagnostics Operations, Inc.
18669414 METHOD, AN APPARATUS, AN ASSEMBLY AND A SYSTEM SUITABLE FOR DETERMINING A CHARACTERISTIC PROPERTY OF A MOLECULAR INTERACTION Final Rejection FIDA BIOSYSTEMS APS
16978638 SYSTEMS AND METHODS OF DIAGNOSING AND PROGNOSING CANCER Non-Final OA THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE
18634737 Chronic Disease Management Test to Inform Clinical Care of Patients with Chronic Conditions Final Rejection Aegis Sciences Corporation
16766956 DETECTION OF BIOMARKERS Non-Final OA Imperial College of Science, Technology and Medicine
17907395 PROGNOSTIC MARKERS OF DISEASE RECURRENCE IN LIVER TRANSPLANT RECIPIENTS WITH HEPATOCELLULAR CARCINOMA Non-Final OA Universiteit Gent

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month